Carisbamate - SK biopharmaceuticals

Drug Profile

Carisbamate - SK biopharmaceuticals

Alternative Names: Comfyde; JNJ-10234094; RWJ-333369; YKP-509

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK biopharmaceuticals
  • Developer Janssen Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Ortho-McNeil Pharmaceutical; SK biopharmaceuticals
  • Class Antiepileptic drugs; Carbamates; Neuroprotectants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy
  • Discontinued Diabetic neuropathies; Essential tremor; Migraine; Postherpetic neuralgia

Most Recent Events

  • 23 Apr 2012 Carisbamate receives Orphan Drug status for Infantile spasms in USA
  • 01 Aug 2010 Johnson & Johnson completes a phase III trial in patients with partial onset seizures (adjunctive treatment) in USA
  • 17 Apr 2010 Adverse events data from 3 phase I trials in Healthy volunteers presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top